Abstract
Background The SARS-CoV-2 pandemic demonstrated the vulnerability of our societies to aerosol transmitted pathogens. With no less than 260mio known cases and > 5mio deaths, SARS-CoV-2 is a global catastrophe leading to human and economic losses unprecedented in recent history. Thus, effective methods to limit the spread of aerosol transmitted pathogens are needed. Universal masking and curfew laws are effective but no permanent solution.
Methods A mass producible LED light source emitting homogeneous parallel UV-C light was used as a “light-barrier” to block the spread of infectious aerosols. In an aerosol test channel, Gram-negative and Gram-positive bacteria as well as coronavirus were nebulized and inactivation rates were determined.
Findings With air speeds of 0.1 m s-1 an exposure time of 1 s in the UV-C light is obtained. Reduction in CFU for E. coli was >3log10 and for S. aureus ∼2.8log10. Plug-forming-units of the murine coronavirus (Mouse Hepatitis Virus, MHV) were reduced by about 3log10.
Interpretation The concept of a UV-C light barrier to ward off infectious aerosols if feasible and possible with a light element as described here. Coupled with sensor based activation/deactivation, such a technology could greatly reduce the transmission rates of aerosol transmitted pathogens while not disturbing natural human behaviour. This is an interesting technology allowing a “new normal” in societies after/with SARS-CoV-2.
Competing Interest Statement
AW, CH, MR, and AvB received material and/or financial support from smart united; AW is involved in IP in relation to the product, CH, AW and MR are direct or indirect shareholders of smart united.
Funding Statement
This study was supported by the provision of materials from smart united.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Jessica Beyerl: beyerl{at}mvp.lmu.de
Albrecht von Brunn: vonBrunn{at}mvp.lmu.de
Vincent Rieker: vrieker{at}stud.hs-heilbronn.de
Marcus Rieker: marcus.rieker{at}htw-dresden.de
Michael Hoelscher: Hoelscher{at}lrz.uni-muenchen.de
Data Availability
Raw data will be made available upon reasonable request to fellow colleagues in the field.